Skip to main content
. Author manuscript; available in PMC: 2023 Oct 6.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2023 Jun 1;32(6):741–743. doi: 10.1158/1055-9965.EPI-22-1307

Table 2. Projection of Prostate Cancer Mortality Reduction in a Hypothetical Screening Trial Ignoring and Preserving Subtypes According to their Distribution Among Late-Stage Diagnoses.

Box 1: Inputs to Mortality Reduction Projection
Low Grade High Grade Total
(A) Years of follow-up 10
(B) Incidence Hazard 0.005
(C) Distribution of Cases
   Early Stage 66% 13% 80%
   Late Stage 8% 13% 20%
   Total 74% 26% 100%
(D) Mortality Hazard
   Early Stage 0.017 0.087 0.026
   Late Stage 0.161 0.258 0.209
   Total 0.026 0.138 0.045
 
Box 2: Mortality Reduction Projection
Low Grade High Grade Total
(E) Stage Shift Multiplier 0.399 0.292 0.437
(F) Stage Shift 11% 19% 30%
  Mortality Reduction
(G) Projected Ignoring Grade 13%
(H) Projected Preserving Grade 5% 5% 10%
(I) Absolute Difference +3%
(J) Relative Difference +31%
  • (A)
    Years of follow-up for hypothetical trial
  • (B)
    Incidence hazard of prostate cancer estimated from SEER (9 registries, Nov 2004 submission) for men ages 50-59 years in 1980-1984
  • (C)
    Distribution of cases from SEER for men diagnosed ages 50-59 years in 1980-1984
  • (D)
    Hazard of mortality following diagnosis, derived from SEER 10-year survival rates, assuming a constant hazard of mortality.
  • (E)
    Stage-shift multipliers calculated as in Owens et al. [5], see formulas G and H in that text. The inputs to these values are the length of follow-up (A), overall incidence rate of the disease (B), the rates at which the disease is diagnosed in each stage (C), and stage-specific survival rates (D). The calculation is performed with all grades combined, and then separately by grade using the corresponding inputs. This value is used below to convert a percent reduction in late-stage disease (F) to a percent reduction in disease-specific mortality (G, H).
  • (F)
    Percent reduction in late-stage cases. Hypothetical value of 30% in screening arm, allocated between grades proportional to late-stage case mix (C).
  • (G)
    = (E) x (F) in total
  • (H)
    = (E) x (F) for each grade separately and summed across grades
  • (I) and (J)
    Absolute and relative differences of projection in total compared to projection by grades